Literature DB >> 16714207

The effect of overexpression of endothelial nitric oxide synthase on eosinophilic lung inflammation in a murine model.

Kazuyuki Kobayashi1, Yoshihiro Nishimura, Tomoya Yamashita, Teruaki Nishiuma, Miyako Satouchi, Mitsuhiro Yokoyama.   

Abstract

The effects of nitric oxide (NO) on allergic inflammation are controversial. In particular, the role of endothelial nitric oxide synthase (eNOS) in asthma remains uncertain. In the present study, we examined the effects of overexpression of eNOS on allergic inflammation using eNOS transgenic (eNOS-Tg) mice, in which eNOS protein is overexpressed in the vascular endothelium and airway epithelium. We found that eNOS-Tg mice showed a reduction of the asthmatic response to allergen challenge. Eosinophilic accumulation in the airspaces, eosinophilic activity, and bronchial responsiveness to acetylcholine were significantly attenuated in eNOS-Tg mice, as compared with wild-type mice following ovalbumin sensitization/challenge, even though the levels of circulating eosinophils were comparable in the wild-type and eNOS-Tg mice. The concentrations of eotaxin in the bronchoalveolar lavage fluid were significantly less in eNOS-Tg mice than in the wild-type mice. In addition, immunohistochemical analysis showed that the expressions of both intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 on the pulmonary endothelium of eNOS-Tg mice was decreased compared with the controls. These results suggest that chronic eNOS overexpression contributes to the suppression of allergic inflammation by reducing the production of eotaxin in the airspaces and/or the expression of adhesion molecules in the vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16714207     DOI: 10.1016/j.intimp.2005.09.016

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  Nitric oxide synthase enzymes in the airways of mice exposed to ovalbumin: NOS2 expression is NOS3 dependent.

Authors:  Jennifer M Bratt; Keisha Williams; Michelle F Rabowsky; Michael S Last; Lisa M Franzi; Jerold A Last; Nicholas J Kenyon
Journal:  Mediators Inflamm       Date:  2010-10-05       Impact factor: 4.711

2.  Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration.

Authors:  Karina Ckless; Anniek Lampert; Jessica Reiss; David Kasahara; Matthew E Poynter; Charles G Irvin; Lennart K A Lundblad; Ryan Norton; Albert van der Vliet; Yvonne M W Janssen-Heininger
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 3.  Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives.

Authors:  Harm Maarsingh; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

4.  Competitive metabolism of L-arginine: arginase as a therapeutic target in asthma.

Authors:  Jennifer M Bratt; Amir A Zeki; Jerold A Last; Nicholas J Kenyon
Journal:  J Biomed Res       Date:  2011-09

5.  Nitric oxide in asthma physiopathology.

Authors:  Carla M Prado; Mílton A Martins; Iolanda F L C Tibério
Journal:  ISRN Allergy       Date:  2011-04-19

6.  Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline.

Authors:  Xiu-Fen Ming; Angana Gupta Rajapakse; João Miguel Carvas; Jean Ruffieux; Zhihong Yang
Journal:  BMC Cardiovasc Disord       Date:  2009-03-13       Impact factor: 2.298

7.  Anti-interleukin-33 Reduces Ovalbumin-Induced Nephrotoxicity and Expression of Kidney Injury Molecule-1.

Authors:  Geun Ho Park; Helen Ki Shinn; Ju-Hee Kang; Won Ju Na; Young Hyo Kim; Chang-Shin Park
Journal:  Int Neurourol J       Date:  2016-06-24       Impact factor: 2.835

Review 8.  An update on the diagnostic biomarkers for asthma.

Authors:  Rashmi Pandey; Ved Parkash; Surya Kant; Ajay K Verma; S N Sankhwar; Avinash Agrawal; Devendra Parmar; Sheetal Verma; Md Kaleem Ahmad
Journal:  J Family Med Prim Care       Date:  2021-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.